Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:10 PM ET 8-K
Clinical Trial Data Korro Bio, Inc. KRRO

Korro Bio Clinical Trial Data

Korro Bio announced the dosing of the first cohort of participants in its ANCHOR Phase 1/2 clinical trial for KRRO-121, an RNA-editing oligonucleotide targeting hyperammonemia in patients with urea cycle disorders (UCD). The trial is currently enrolling healthy volunteers in Australia for safety and PK evaluation, with dosing in UCD patients expected to begin in the first half of 2027.

“Dosing the first cohort in ANCHOR is a step towards gaining evidence on safety first and then activity. Providing the potential for peace of mind for patients with a UCD, irrespective of their mutational background, is something we hope to demonstrate through this trial.”

Ram Aiyar, PhD, Chief Executive Officer and President of Korro
4:02 PM ET 8-K
Regulatory Approval Endovia Health Sciences, Inc. EDVA

Endovia Health Sciences Regulatory Approval

Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined its investigational drug CannEpil qualifies as a 'minor use' under the MUMS program for canine bone cancer pain. This designation allows the company to pursue a conditional approval pathway, which facilitates earlier market availability while additional effectiveness data is collected. The company is targeting a potential U.S. veterinary product launch in 2027.

Counterparty
Lupvindol BioSciences
4:02 PM ET 8-K
M&A Deal Peoples Bancorp Inc PEBO

Peoples Bancorp M&A Deal with Capital Bancorp, Inc.

Peoples Bancorp Inc. (PEBO) has entered into a definitive agreement to acquire Rockville, Maryland-based Capital Bancorp, Inc. Management described the transaction as a transformational combination that adds scale and a differentiated set of businesses to the Peoples franchise.

Counterparty
Capital Bancorp, Inc.
4:00 PM ET 8-K
Nasdaq/NYSE Compliance Notice Purple Innovation, Inc. PRPL

Purple Innovation Nasdaq/NYSE Compliance Notice

Purple Innovation received a deficiency notice from Nasdaq on September 30, 2026, because its Market Value of Publicly Held Shares (MVPHS) fell below the $15 million minimum requirement for 30 consecutive business days. The company has 180 calendar days, or until March 29, 2026, to regain compliance by maintaining a MVPHS of at least $15 million for ten consecutive business days. If compliance is not regained, the company may face delisting or seek a transfer to the Nasdaq Capital Market.

Counterparty
Nasdaq
Term
180 days
3:47 PM ET 8-K
Capital Raise Franklin BSP Real Estate Debt, Inc.

Franklin BSP Real Estate Debt Capital Raise of $9.16M

Franklin BSP Real Estate Debt, Inc. sold 369,471.30 shares of its Class G, G-S, E, and I common stock for aggregate consideration of approximately $9.16 million. The sale was conducted as part of the company's continuous private offering under Regulation D exemptions. The shares were sold at prices ranging from $24.60 to $24.91 per share depending on the class.

Value
$9.16M
2:25 PM ET 8-K
Divestiture Omnitek Engineering Corp OMTK

Omnitek Engineering Divestiture to Omnitek Corp.

Omnitek Engineering Corp. sold substantially all of its assets related to its diesel-to-alternative-fuel engine conversion business to Omnitek Corp. (Buyer). Following the divestiture and the acquisition of Hard Rock Ready Mix, LLC, the company has transitioned its core business operations to the ready-mix concrete industry in North Carolina.

Counterparty
Omnitek Corp.
1:09 PM ET 8-K
Nasdaq/NYSE Compliance Notice SCWorx Corp. WORX

SCWorx Nasdaq/NYSE Compliance Notice

The Nasdaq Hearings Panel has granted SCWorx Corp.'s request for reconsideration and determined the company has regained compliance with Nasdaq's minimum bid price and publicly held shares requirements. Trading on The Nasdaq Capital Market is expected to be reinstated shortly, subject to a one-year discretionary panel monitor and monthly reporting requirements. The company successfully increased its public float through a private placement and warrant exercises to meet the 500,000-share minimum threshold.

Counterparty
Nasdaq
Term
1 year
12:38 PM ET 8-K
Nasdaq/NYSE Compliance Notice Ceco Environmental Corp CECO

Ceco Environmental Nasdaq/NYSE Compliance Notice

CECO Environmental Corp. is voluntarily withdrawing its primary stock listing from the Nasdaq Global Select Market and transferring it to the Texas Stock Exchange (TXSE). The company expects to cease trading on Nasdaq on October 16, 2026, and begin trading on the TXSE on October 19, 2026, under its existing ticker symbol 'CECO'.

Counterparty
Texas Stock Exchange LLC
9:40 AM ET 8-K
Capital Raise Narragansett Bancorp, Inc. NARA

Narragansett Bancorp Capital Raise

Narragansett Bancorp, Inc. has completed its subscription offering in connection with the two-tier holding company reorganization of BayCoast Bank. The offering was oversubscribed by depositors, meaning no community or syndicated offering is expected, though final closing remains subject to regulatory approval.

9:25 AM ET 8-K
Divestiture Duos Technologies Group, Inc. DUOT

Duos Technologies Group Divestiture to Axe Compute, Inc. for $131M

Duos Technologies Group, Inc. sold 100% of its GPU-as-a-Service subsidiary, Duos Edge AI – GPUaaS, LLC, to Axe Compute, Inc. for a total consideration including the repayment of $87.8 million in debt and a deferred purchase price of $42.9 million ($715,000 per month for 60 months). The divestiture allows Duos to transition into a pure-play AI colocation landlord, focusing on modular data center infrastructure rather than owning compute hardware.

Value
$131M
Counterparty
Axe Compute, Inc.
Term
60 months
9:17 AM ET 8-K
M&A Deal Construction Partners, Inc. ROAD

Construction Partners M&A Deal with J.H. Strain & Sons, Inc.

Construction Partners, Inc. (CPI) has completed the acquisition of the asphalt manufacturing and construction assets of J.H. Strain & Sons, Inc., based in Tye, Texas. The deal adds two hot-mix asphalt plants and over 125 employees to CPI's Texas platform, Lone Star Paving, expanding its presence in the Abilene and West Texas markets.

Counterparty
J.H. Strain & Sons, Inc.

“The addition of J.H. Strain’s two hot-mix asphalt plants, fleet and experienced workforce provides Lone Star with a strong local presence from which to serve public and private infrastructure customers throughout the greater Abilene area and West Texas.”

Fred J. (Jule) Smith, III, the Company’s President and Chief Executive Officer
9:07 AM ET 8-K
M&A Deal iRhythm Holdings, Inc. IRTC

iRhythm Holdings Signs $238M M&A Deal with Vital Connect, Inc.

iRhythm Holdings completed its acquisition of Vital Connect, Inc. for $237.5 million in cash. The deal expands iRhythm's cardiac monitoring portfolio into mobile cardiac telemetry (MCT) and multi-vitals monitoring across ambulatory, inpatient, and hospital-to-home care settings.

Value
$238M
Counterparty
Vital Connect, Inc.
9:01 AM ET 8-K
Product Launch Vida Global Inc. VIDA

Vida Global Product Launch

VIDA Global Inc. introduced outcome-based billing for its AI digital employees, a new pricing model that charges customers for verified results rather than usage. The model allows businesses to pay for specific outcomes such as lead qualification or customer onboarding, and is initially targeting performance marketing and insurance industries.

8:44 AM ET 8-K
M&A Deal Qorvo, Inc. QRVO

Qorvo M&A Deal with Skyworks Solutions, Inc.

Qorvo, Inc. completed its previously announced merger with Skyworks Solutions, Inc., becoming a wholly owned subsidiary of Skyworks. Under the terms of the agreement, Qorvo stockholders received 0.960 shares of Skyworks common stock for each share of Qorvo common stock held. In connection with the closing, Qorvo terminated its existing credit agreement with Bank of America.

Counterparty
Skyworks Solutions, Inc.
8:43 AM ET 8-K
M&A Deal Skyworks Solutions, Inc. SWKS

Skyworks Solutions M&A Deal with Qorvo, Inc.

Skyworks Solutions completed its acquisition of Qorvo, Inc. in a cash-and-stock merger where Qorvo stockholders received $32.50 in cash and 0.960 shares of Skyworks common stock per share. The combined company expects to realize over $500 million in annual cost synergies and will continue to trade under the ticker SWKS.

Counterparty
Qorvo, Inc.
8:40 AM ET 8-K
Nasdaq/NYSE Compliance Notice ESS Tech, Inc. GWHT

ESS Tech Nasdaq/NYSE Compliance Notice

The NYSE has suspended trading of ESS Tech's common stock and commenced delisting proceedings because the company's average global market capitalization fell below the $15 million minimum requirement over a 30-day period. The company's stock has transitioned to the over-the-counter market under the ticker GWHT, though ESS Tech intends to request a review of the delisting determination. This follows a previous delisting notice received in September 2026 regarding a separate listing standard violation.

Counterparty
New York Stock Exchange
8:35 AM ET 8-K
M&A Deal Axe Compute Inc. AGPU

Axe Compute Signs $131M M&A Deal with Duos Technologies Group, Inc.

Axe Compute acquired 100% of a special purpose vehicle from Duos Technologies Group that owns an AI cluster in Georgia consisting of 2,304 NVIDIA B300 GPUs. The transaction involved retiring $87.8 million in debt and a $42.9 million deferred purchase price, while simultaneously extending the cluster's customer agreement to a five-year term expected to generate $364.6 million in revenue.

Value
$131M
Counterparty
Duos Technologies Group, Inc.
Term
5 years

“In another validation of our partnership with Duos, we are taking this step so we can both focus on what we do best. Duos is a world class data center builder and we are fortunate to call them a partner. Our customer is committed for five years, our power and facility costs are covered for five years, and we own our GPUs. That alignment is expected to significantly expand the margin profile and return on this existing cluster.”

Christopher Miglino, Chief Executive Officer of Axe Compute

“This is the right move for both companies, and our relationship with Axe Compute has never been stronger. It streamlines the Georgia structure so Axe Compute can focus on what it does exceptionally well, delivering AI clusters to its customers. Duos stays focused on what we do best, providing the power and infrastructure behind them, now under a five-year partnership.”

Doug Recker, Chief Executive Officer of Duos Technologies Group
8:32 AM ET 8-K
M&A Deal SIM Acquisition Corp. I SIMA

SIM Acquisition Corp. I M&A Deal with American Industrial Technologies, Inc.

SIM Acquisition Corp. I entered into a binding Letter of Intent to acquire 100% of American Industrial Technologies, Inc. (AIT) in a business combination. Upon closing, SIM will issue approximately 50,000,000 shares to AIT equity holders, and AIT's CEO John Chiorando will become the CEO and Chairman of the combined company. The agreement includes a $5 million termination fee payable to SIM under certain conditions if the deal fails to proceed.

Counterparty
American Industrial Technologies, Inc.
8:32 AM ET 8-K
Divestiture Innovate Corp. VATE

Innovate Divestiture to IES Holdings, Inc. for $524M

INNOVATE Corp. completed the sale of its 91.21% stake in DBM Global, Inc. to IES Holdings for approximately $378 million in cash and 430,974 shares of IES common stock valued at $146 million. The company used the proceeds to repay approximately $89.4 million in outstanding debt across two credit facilities and intends to use remaining net proceeds to further reduce its debt obligations.

Value
$524M
Counterparty
IES Holdings, Inc.
8:30 AM ET 8-K
Capacity Expansion Evolution Metals & Technologies Corp. EMAT

Evolution Metals & Technologies Capacity Expansion

Evolution Metals & Technologies Corp. (EMAT) announced it will hold a ribbon-cutting ceremony on December 17, 2026, for its newest and largest high-performance rare earth magnet facility in Pohang, South Korea. The flagship facility anchors a phased expansion targeting over 10,000 metric tons of annual production capacity to provide a non-China supply source for U.S. defense and automotive markets. The expansion is strategically timed ahead of January 2027 U.S. defense sourcing restrictions on Chinese-origin magnets.

“On December 17, we will publicly inaugurate what we believe is the largest high-performance magnet facility in production outside of China. This is a first step in taking production the Company has already proven in Korea to the next level. With DFARS 252.225-7052 taking effect on January 1, 2027 to restrict Chinese-origin rare earth magnets in qualifying U.S. defense systems, and following the August 13, 2026, White House proclamation imposing a 100 percent tariff on the most sensitive foreign unmanned aircraft and certain parts, the demand for secure supply chains is urgent.”

David Wilcox, Executive Chairman of EM&T
8:30 AM ET 8-K
Clinical Trial Data Coya Therapeutics, Inc. COYA

Coya Therapeutics Clinical Trial Data

Coya Therapeutics announced it has achieved full enrollment of 120 patients in its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The company expects to release topline data from the double-blind treatment phase in early Q2 2027.

8:22 AM ET 8-K
Partnership Leidos Holdings, Inc. LDOS

Leidos Holdings Partnership with Altaris, LLC

Leidos and investment firm Altaris completed the formation of a joint venture named Nickel JV Ultimate Parent, LLC (operating under the Analogic brand) by combining Leidos' Security Enterprise Solutions and Industrial Automation businesses with Analogic Corporation. Leidos retains a 41.5% minority ownership stake in the JV, while Altaris affiliates hold 58.5% and majority board control.

Counterparty
Altaris, LLC

“This JV creates an American innovator with the technology, talent and scale to address rapidly evolving global security screening needs. Its launch also sharpens our focus on the growth engines driving our NorthStar 2030 strategy.”

Tom Bell, Leidos Chief Executive Officer

“The strategic combination of these two businesses into one reinforces our commitment to the important national security missions and markets we serve.”

Tom Bell, Leidos Chief Executive Officer
8:22 AM ET 8-K
Capacity Expansion Terawulf Inc. WULF

Terawulf Capacity Expansion

TeraWulf Inc. entered into amended agreements with Kentucky Power to double the contracted power capacity at its Muskie Data Campus from 500 MW to 1 GW. The agreement also accelerates the delivery timeline for the second 500 MW phase from 2030 to 2029 to meet high customer demand for AI and high-performance computing infrastructure.

Counterparty
Kentucky Power Company
Term
through 2029

“Customer interest in Muskie has been tremendous, and power availability is central to those conversations. Securing the next 500 MW and moving its planned delivery into 2029 gives us greater flexibility to meet prospective customers’ deployment needs.”

Paul Prager, Chairman and Chief Executive Officer of TeraWulf
8:21 AM ET 8-K
M&A Deal C. H. Robinson Worldwide, Inc. CHRW

C. H. Robinson Worldwide Signs $5.8B M&A Deal with RXO, Inc.

C.H. Robinson Worldwide, Inc. has entered into a definitive agreement to acquire RXO, Inc. in a stock-and-cash transaction with an implied value of $5.8 billion. The deal combines two major North American third-party logistics providers and is expected to generate $300 million in annual cost synergies within two years of closing. The transaction is expected to close in the first half of 2027, creating a combined company with an enterprise value of over $25 billion.

Value
$5.8B
Counterparty
RXO, Inc.
Earnings call
Oct 2, 2026, 8:00 AM ET

“This transaction is a natural next step in our transformation, allowing us to create a more scaled, resilient North American third-party logistics provider positioned to offer exceptional customer service and redefine the future of our industry.”

Dave Bozeman, C.H. Robinson President and Chief Executive Officer

“Joining C.H. Robinson represents an exciting next chapter for our company, our employees and our customers. We have built a strong business by staying relentlessly focused on our customers, operating with agility and delivering solutions that help them navigate an increasingly complex supply chain.”

Drew Wilkerson, RXO Chairman and Chief Executive Officer
8:17 AM ET 8-K
M&A Deal RXO, Inc. RXO

RXO Signs $5.8B M&A Deal with C.H. Robinson Worldwide, Inc.

RXO, Inc. has entered into a definitive agreement to be acquired by C.H. Robinson in a stock-and-cash transaction with an implied value of $5.8 billion. RXO stockholders can elect to receive $30.25 in cash, 0.1992 shares of C.H. Robinson stock, or a standard combination of both per share. The deal is expected to close in the first half of 2027 and create a combined logistics company with an enterprise value exceeding $25 billion.

Value
$5.8B
Counterparty
C.H. Robinson Worldwide, Inc.
Earnings call
Oct 2, 2026, 8:00 AM ET
8:08 AM ET 8-K
M&A Deal Benitec Biopharma Inc. BNTC

Benitec Biopharma M&A Deal with U.S. Food and Drug Administration

Benitec Biopharma provided a status and timeline update for its BB-301 program following a Type C meeting with the FDA. The company remains on track to initiate a pivotal study in mid-2027, with the final study design expected to be confirmed in Q1 2027 after the FDA reviews additional natural history data.

Counterparty
U.S. Food and Drug Administration
8:07 AM ET 8-K
Capital Raise Flex Ltd. FLEX

Flex Capital Raise of $2B

Flex Ltd. entered into an agreement to sell $2.0 billion of Series A Convertible Preferred Stock in its Cloud and Power Infrastructure subsidiary, Axiom Solutions International, to a group led by General Catalyst and Koch Equity Development. The proceeds will fund Axiom's acquisition of EPC Power Corp and support its balance sheet ahead of a planned spin-off into an independent public company in Q1 2027. Flex is guaranteeing the investment, which includes a redemption obligation if the spin-off is not completed by the end of 2027.

Value
$2B
Counterparty
General Catalyst

“This investment provides equity funding for our recently announced acquisition of EPC Power and will allow Axiom to have a strong balance sheet as we prepare to stand up as an independent, publicly traded company squarely focused on the power, thermal, and compute infrastructure the AI era demands.”

Revathi Advaithi, Chief Executive Officer of Flex and expected Chief Executive Officer of Axiom

“Axiom sits at the center of the power and infrastructure buildout that AI demands, and we’ve been impressed by the team’s execution and the scale of the opportunity ahead.”

Hemant Taneja, Chief Executive Officer, General Catalyst
8:05 AM ET 8-K
Regulatory Approval Tela Bio, Inc. TELA

Tela Bio Regulatory Approval

TELA Bio received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. This marks a significant milestone as it is the first fully resorbable synthetic product in the company's portfolio to be designed and produced in-house.

“FDA 510(k) clearance is a significant milestone for TELA Bio as Liora is the first fully resorbable synthetic product in our portfolio to be designed and produced in-house by our team of innovative engineers.”

Heather Getz, CEO of TELA Bio
8:05 AM ET 8-K
Partnership Forum Markets Inc FRMM

Forum Markets Partnership with Edge Node Inc.

Forum Markets and Edge Node Inc. formed a joint venture, Forum Edge AI LLC, to deploy and operate high-performance inference AI compute infrastructure across the U.S. Forum holds a 51% controlling interest in the JV, which will utilize existing data centers and mobile communications tower sites to provide GPU capacity to long-term offtake partners.

Counterparty
Edge Node Inc.
8:01 AM ET 8-K
Clinical Trial Data Vaxcyte, Inc. PCVX

Vaxcyte Clinical Trial Data

Vaxcyte announced positive topline results from its OPUS-1 pivotal Phase 3 trial of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate for adults. The trial met all prespecified primary immunogenicity and safety endpoints, demonstrating noninferiority to Prevnar 20 and Capvaxive. These results will support a planned Biologics License Application (BLA) submission to the FDA in the first half of 2028.

Earnings call
Oct 5, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.